← Back to feed

Renalytix (

RENX · AIM · Health Care · mcap £39m today, £40m on 2 Oct

Activist arrives · Early 1/3

Pattern evidence · every line sourced

Activist stake, 2 Oct: LONDON and NEW YORK, 1 October 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, announces that on 29 September 2026, certain investment vehicles connected with Christopher Mills, Non-Executive Director, have completed the... RNS
Watch: next signal would be “AGM revolt” – A resolution fails or draws a large vote against, within 365 days.

AI summary with checked claims arrives with the nightly run. These lines are the matched extracts.

All announcements

All RNS · 103 Key events · 31 Pattern signals · 1

05 Oct 26

Holding(s) in Company
RNS 9806723 ↗
02 Oct 26

SIGNAL 1 Activist stake

Harwood Capital LLP*, Christopher Mills, Non-Executive Chairman, Chief Investment Officer of Harwood – Purchase of Ordinary Shares; 1,166,667
Director/PDMR Shareholding (Replacement) · RNS 9805076 ↗
02 Oct 26

Holding(s) in Company
RNS 9805069 ↗
01 Oct 26

Holding(s) in Company
RNS 9802763 ↗
01 Oct 26

Director/PDMR Shareholding Director buysActivist stake

LONDON and NEW YORK, 1 October 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, announces that on 29 September 2026, certain investment vehicles connected with Christopher Mills,...
RNS 9802753 ↗
01 Oct 26

Holding(s) in Company
RNS 9801422 ↗
30 Sep 26

Holding(s) in Company
RNS 9798947 ↗
28 Sep 26

Result of General Meeting

LONDON and NEW YORK, 28 September 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, announces that at the General Meeting (“GM”) held earlier today, all resolutions were passed.
RNS 9794377 ↗
28 Sep 26

Directorate Change

Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focussed on kidney disease, announces that Julian Baines MBE has indicated his intention to stand down as Non-Executive Chair of Renalytix on 31 December 2026.
RNS 9792805 ↗
25 Sep 26

Investor Presentations

LONDON and NEW YORK, 25 September 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, announces that it will host a live online investor presentation next week and will be presenting at the...
RNS 9792120 ↗
16 Sep 26

Holding(s) in Company
RNS 9775785 ↗
16 Sep 26

Holding(s) in Company
RNS 9775768 ↗
16 Sep 26

Additional CEO Share Purchase

LONDON and NEW YORK, 16 September 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, announces that on 11 September and 15 September 2026 James McCullough, Chief Executive Officer, bought a...
RNS 9775262 ↗
14 Sep 26

Holding(s) in Company
RNS 9771235 ↗
14 Sep 26

New Accounting Ref Date

Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focussed on kidney disease, announces that it has resolved to change the Company's accounting reference date.
RNS 9770310 ↗
11 Sep 26

Holding(s) in Company
RNS 9768620 ↗
11 Sep 26

Holding(s) in Company
RNS 9767038 ↗
11 Sep 26

CEO Share Purchase

LONDON and NEW YORK, 11 September 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, announces that on 8 September 2026 and 9 September 2026 James McCullough, Chief Executive Officer, bought...
RNS 9766690 ↗
10 Sep 26

Holding(s) in Company
RNS 9766313 ↗
09 Sep 26

Holding(s) in Company
RNS 9764103 ↗
09 Sep 26

Holding(s) in Company
RNS 9764058 ↗
08 Sep 26

Posting of Circular and Notice of AGM
RNS 9761666 ↗
08 Sep 26

Holding(s) in Company
RNS 9761568 ↗
08 Sep 26

Holding(s) in Company
RNS 9761567 ↗
08 Sep 26

Capital Access Window - Renalytix Plc

RNS 9760526 ↗
08 Sep 26

Result of WRAP Retail Offer

Renalytix is pleased to announce, further to its announcement of 3 September 2026, the completion of the WRAP Retail Offer at an issue price of £0.06 per Ordinary Share (the "Placing Price").
RNS 9759852 ↗
04 Sep 26

Holding(s) in Company
RNS 9757176 ↗
03 Sep 26

WRAP Retail Offer for up to £1,000,000

Renalytix is pleased to announce a retail offer via the Winterflood Retail Access Platform ("WRAP") to raise up to £1,000,000 (the "WRAP Retail Offer") through the issue of new ordinary shares of £0.0025 each in the capital of the Company (the "Ordinary Shares").
RNS 9753045 ↗
03 Sep 26

Result of Fundraise

Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focussed on kidney disease, confirms that, further to the Company's announcement released at 7.01 a.m. on 1 September 2026 (RNS Number: 8254S) (the "Fundraising...
RNS 9752873 ↗
02 Sep 26

Holding(s) in Company
RNS 9752638 ↗
01 Sep 26

Holding(s) in Company
RNS 9749312 ↗
01 Sep 26

Capital Access Window - Renalytix plc

RNS 9748669 ↗
01 Sep 26

Proposed Fundraise

596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED ("UK MAR").
RNS 9747833 ↗
01 Sep 26

Collaboration with Quest Diagnostics

Collaboration with Quest Diagnostics to expand kidneyintelX.dkdTM testing in the United States
RNS 9747173 ↗
24 Aug 26

AIM Rule 17 Disclosure

LONDON and NEW YORK, 24 August 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focussed on kidney disease, provides the following update pursuant to Rule 17 and Schedule 2 (g) (v) of the AIM Rules.
RNS 9737226 ↗
10 Aug 26

Holding(s) in Company
RNS 9714069 ↗
29 Jul 26

Holding(s) in Company
RNS 9694421 ↗
27 Jul 26

Holding(s) in Company
RNS 9689617 ↗
07 Jul 26

Holding(s) in Company
RNS 9656964 ↗
30 Jun 26

Real world evidence study data published

· Landmark study of 2,470 patients across two U.S. health systems demonstrates sustained risk prognosis, improvements in kidney function, increases in guideline-directed therapy uptake, and measurable reduction in individual patient risk trajectories over 24 months
RNS 9643051 ↗
29 May 26

Holding(s) in Company
RNS 9592887 ↗
27 May 26

Holding(s) in Company
RNS 9587754 ↗
18 May 26

Holding(s) in Company
RNS 9573890 ↗
05 May 26

Holding(s) in Company
RNS 9553241 ↗
05 May 26

Holding(s) in Company
RNS 9552366 ↗
01 May 26

Holding(s) in Company
RNS 9548968 ↗
29 Apr 26

Holding(s) in Company
RNS 9544944 ↗
23 Apr 26

Holding(s) in Company
RNS 9535247 ↗
23 Apr 26

Holding(s) in Company
RNS 9535241 ↗
22 Apr 26

Key milestones achieved for kidneyintelX.dkd

Key regulatory milestones achieved in support of scaling of kidneyintelX.dkd
RNS 9531549 ↗
16 Apr 26

Holding(s) in Company
RNS 9524714 ↗
16 Apr 26

Holding(s) in Company
RNS 9523590 ↗
09 Apr 26

Holding(s) in Company
RNS 9513360 ↗
07 Apr 26

Holding(s) in Company
RNS 9508992 ↗
07 Apr 26

Holding(s) in Company
RNS 9508991 ↗
30 Mar 26

Holding(s) in Company
RNS 9498788 ↗
26 Mar 26

Half-year Results

LONDON and NEW YORK, 26 March, 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, whose product kidneyintelX.dkd , is the only FDA-approved and Medicare-reimbursed prognostic test to support early-stage risk...
RNS 9492532 ↗
18 Mar 26

Holding(s) in Company
RNS 9480845 ↗
17 Mar 26

Holding(s) in Company
RNS 9478342 ↗
13 Mar 26

Holding(s) in Company
RNS 9474167 ↗
27 Feb 26

Holding(s) in Company
RNS 9449915 ↗
13 Feb 26

Further CEO Share Purchase

LONDON and NEW YORK, 13 February 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, whose product kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test to support early-stage risk...
RNS 9430854 ↗
13 Feb 26

Director/PDMR Shareholding Director buys

LONDON and NEW YORK, 13 February 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, whose product kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test to support early-stage risk...
RNS 9429127 ↗
12 Feb 26

Director/PDMR Share Purchase Director buys

LONDON and NEW YORK, 12 February 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, whose product kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test to support early-stage risk...
RNS 9427087 ↗
12 Feb 26

CEO Share Purchase

LONDON and NEW YORK, 12 February 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, whose product kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test to support early-stage risk...
RNS 9426863 ↗
11 Feb 26

H1 Trading update

LONDON and NEW YORK, 11 February 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, whose product kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test to support early-stage risk...
RNS 9424676 ↗
21 Jan 26

Holding(s) in Company
RNS 9373217 ↗
15 Jan 26

Holding(s) in Company
RNS 9356767 ↗
12 Jan 26

Three kidneyintelX.dkd Clinical Integrations

LONDON and NEW YORK, 12 January 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in...
RNS 9346467 ↗
09 Jan 26

Holding(s) in Company
RNS 9344643 ↗
06 Jan 26

Holding(s) in Company
RNS 9336973 ↗
24 Dec 25

Holding(s) in Company
RNS 9318501 ↗
23 Dec 25

Holding(s) in Company
RNS 9316259 ↗
19 Dec 25

Holding(s) in Company
RNS 9309359 ↗
17 Dec 25

Holding(s) in Company
RNS 9303728 ↗
16 Dec 25

Holding(s) in Company
RNS 9300526 ↗
09 Dec 25

Result of AGM
RNS 9285166 ↗
09 Dec 25

AGM Statement

LONDON and NEW YORK, 9 December 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in...
RNS 9283718 ↗
27 Nov 25

Holding(s) in Company
RNS 9261888 ↗
25 Nov 25

Holding(s) in Company
RNS 9256610 ↗
25 Nov 25

Plan to Implement ADS Ratio Change

Renalytix Announces Plan to Implement ADS Ratio Change
RNS 9254648 ↗
12 Nov 25

Pivotal kidneyintelX.dkd data published

Pivotal kidneyintelX.dkd data published in Diabetes Care Journal of the American Diabetes Association
RNS 9227737 ↗
05 Nov 25

Holding(s) in Company
RNS 9214904 ↗
04 Nov 25

Publication of Annual Report & Notice of AGM
RNS 9212366 ↗
03 Nov 25

Holding(s) in Company
RNS 9209161 ↗
03 Nov 25

Audited Full Year Fiscal 2025 Results

LONDON and NEW YORK, 3 November 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in...
RNS 9207450 ↗
30 Oct 25

Holding(s) in Company
RNS 9204786 ↗
28 Oct 25

Holding(s) in Company
RNS 9199808 ↗
27 Oct 25

Confirmation of receipt of £860k R&D tax credits

Confirmation of receipt of £860k of R&D tax credits
RNS 9195035 ↗
24 Oct 25

Holding(s) in Company
RNS 9192666 ↗
23 Oct 25

Holding(s) in Company
RNS 9189652 ↗
21 Oct 25

Holding(s) in Company
RNS 9184382 ↗
17 Oct 25

Holding(s) in Company
RNS 9178018 ↗
17 Oct 25

Holding(s) in Company
RNS 9176882 ↗
16 Oct 25

Holding(s) in Company
RNS 9175903 ↗
16 Oct 25

Holding(s) in Company
RNS 9175665 ↗
15 Oct 25

Holding(s) in Company
RNS 9172448 ↗
10 Oct 25

Holding(s) in Company
RNS 9164164 ↗
10 Oct 25

Holding(s) in Company
RNS 9163539 ↗
10 Oct 25

Holding(s) in Company
RNS 9162427 ↗
10 Oct 25

$4m balance sheet improvement with bond conversion

The conversion of the Convertible Bonds will provide a significant improvement to Renalytix's balance sheet, improving the Company's net asset position by approximately $4m and saving up to $1.4m in accrued interest over the remaining life of the loan.
RNS 9162285 ↗
09 Oct 25

Holding(s) in Company
RNS 9161698 ↗
07 Oct 25

Holding(s) in Company
RNS 9156146 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.